<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Fabry disease: Neurologic manifestations</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Fabry disease: Neurologic manifestations</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Fabry disease: Neurologic manifestations</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Marc C Patterson, MD, FRACP</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Scott E Kasner, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John F Dashe, MD, PhD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 20, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Fabry disease (also called angiokeratoma corporis diffusum, ceramide trihexosidosis, and Anderson-Fabry disease) is an X-linked glycolipid storage disease. It is caused by deficient activity of the lysosomal enzyme alpha-galactosidase A, which causes progressive accumulation of alpha-D-galactosyl moieties, such as globotriaosylceramide (the glycolipid substrate for alpha-galactosidase A), within multiple cell types and tissues of affected patients [<a href="#rid1">1</a>]. Numerous mutations have been found in the alpha-galactosidase A gene (<em>GLA</em> gene) on the long arm of the X chromosome (Xq22).</p><p>This topic will review the neurologic manifestations of Fabry disease and their treatment.</p><p>Other clinical aspects of Fabry disease are presented elsewhere. (See  <a class="medical medical_review" href="/z/d/html/7195.html" rel="external">"Fabry disease: Clinical features and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/7207.html" rel="external">"Fabry disease: Treatment and prognosis"</a> and  <a class="medical medical_review" href="/z/d/html/4914.html" rel="external">"Fabry disease: Cardiovascular disease"</a>.)</p><p class="headingAnchor" id="H1021672141"><span class="h1">OVERVIEW</span><span class="headingEndMark"> — </span>Clinical manifestations of Fabry disease usually become evident by 10 years of age in the severe classic form. Initial manifestations typically include neuropathic pain (acroparesthesia), hypohidrosis, poor exercise tolerance, and fever of unknown origin. The characteristic skin lesions known as angiokeratomas develop in the second decade of life. By of the third decade of life, cardiovascular and renal disease become increasingly prominent [<a href="#rid2">2</a>]. An overview of the clinical manifestations of Fabry disease and other related disorders is presented in the table  (<a class="graphic graphic_table graphicRef56567" href="/z/d/graphic/56567.html" rel="external">table 1</a>).</p><p>Progressive accumulation of globotriaosylceramide within endothelial, perithelial, and smooth muscle cells of the vascular system, dorsal root ganglia, and cells of the autonomic nervous system, result in the neurologic manifestations of the disease [<a href="#rid3">3</a>]. These include a small-fiber peripheral neuropathy and an increased propensity for ischemic stroke in affected males and female heterozygotes.</p><p class="headingAnchor" id="H2"><span class="h1">SMALL-FIBER PERIPHERAL NEUROPATHY</span><span class="headingEndMark"> — </span>The length-dependent small-fiber peripheral neuropathy associated with Fabry disease may cause an almost constant discomfort of the hands and feet, with paroxysmal burning pains of the palms and soles [<a href="#rid4">4,5</a>]. Alternatively, it may cause recurrent painful episodes triggered by stress, fever, heat, fatigue, joint pain, or exercise [<a href="#rid6">6</a>]. The pain is sometimes misconstrued as "growth pain." Although pain tends to diminish with age secondary to progressive nerve fiber loss, it may be of sufficient severity to lead to suicide attempts.</p><p>Patients have decreased cold and warm perception that first manifests in the feet associated with decreased epidermal nerve fiber density in the affected regions [<a href="#rid7">7,8</a>]. Electron microscopy of peripheral nerves reveals loss of unmyelinated and small myelinated nerve fibers and lamellar inclusions in the perineurium and the dorsal root ganglia likely consisting of glycosphingolipids [<a href="#rid9">9,10</a>]. Nerve conduction studies are consequently normal [<a href="#rid7">7,8</a>]. A study employing functional magnetic resonance neurography found that patients with Fabry disease had symmetrically enlarged dorsal root ganglia with decreased permeability of the blood-tissue interface, the latter consistent with dysfunctional perfusion [<a href="#rid11">11</a>].</p><p class="headingAnchor" id="H3"><span class="h2">Pain relief</span><span class="headingEndMark"> — </span>The treatment of chronic neuropathic pain in patients with Fabry disease remains empiric [<a href="#rid12">12</a>]. Preventive pain therapy with <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">gabapentin</a>, <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">carbamazepine</a>, and <a class="drug drug_general" data-topicid="8605" href="/z/d/drug information/8605.html" rel="external">amitriptyline</a> appears to be beneficial [<a href="#rid13">13</a>]. All three are approved by the US Food and Drug Administration (FDA) for the treatment of neuropathic pain.</p><p>One potential advantage of anticonvulsants is that compliance may be monitored and the risk of toxicity reduced by following serum levels. However, these levels do not have a direct correlation with neuropathic pain response.</p><p>Narcotic agents should be avoided if possible. Nonsteroidal anti-inflammatory agents should also be avoided, as these tend to be ineffective and may lead to renal toxicity.</p><p class="headingAnchor" id="H4"><span class="h3">Gabapentin and pregabalin</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">Gabapentin</a> and <a class="drug drug_general" data-topicid="9473" href="/z/d/drug information/9473.html" rel="external">pregabalin</a> bind to the voltage-gated calcium channels at the alpha 2-delta subunit and inhibit neurotransmitter release. They have efficacy versus placebo in several neuropathic pain conditions. (See  <a class="medical medical_review" href="/z/d/html/126633.html" rel="external">"Pharmacologic management of chronic non-cancer pain in adults", section on 'Antiseizure medications'</a>.)</p><p>Advantages of <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">gabapentin</a> and <a class="drug drug_general" data-topicid="9473" href="/z/d/drug information/9473.html" rel="external">pregabalin</a> include low toxicity, a low incidence of drug interactions, and lack of liver metabolism.</p><p>In children less than 12 years old, the starting dose of <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">gabapentin</a> is 10 to 15 mg/kg per day divided into three doses. The dose may be slowly increased up to 50 mg/kg daily. For older children and adults the initial dose is typically 300 mg three times per day (900 mg total per day). The maximum total dose may be in the range of 1800 to 2400 mg per day.</p><p>One advantage of <a class="drug drug_general" data-topicid="9473" href="/z/d/drug information/9473.html" rel="external">pregabalin</a> is twice daily dosing compared with three time daily dosing for <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">gabapentin</a>. Pregabalin is usually started at a dose of<strong> </strong>75 mg twice daily; the dose may be increased by the same amount after four to seven days to a typical total daily dose of 300 mg or to a maximum total daily dose of 600 mg as necessary and tolerated [<a href="#rid14">14</a>].</p><p>Both <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">gabapentin</a> and <a class="drug drug_general" data-topicid="9473" href="/z/d/drug information/9473.html" rel="external">pregabalin</a> can produce dose-dependent dizziness and sedation that can be reduced by starting with lower doses and titrating slowly.</p><p>The nearly complete renal clearance for <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">gabapentin</a> and <a class="drug drug_general" data-topicid="9473" href="/z/d/drug information/9473.html" rel="external">pregabalin</a> is potentially concerning in patients with Fabry disease, who are at risk for kidney disease. Therefore, renal function should be assessed before beginning gabapentin treatment and the dose should be adjusted accordingly, as renal function affects serum levels and half-life.</p><p class="headingAnchor" id="H5"><span class="h3">Other anticonvulsants</span><span class="headingEndMark"> — </span>A number of other anticonvulsants have been used for the treatment of neuropathic pain. Of the older drugs, <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">carbamazepine</a> and <a class="drug drug_general" data-topicid="9769" href="/z/d/drug information/9769.html" rel="external">phenytoin</a> have been used most often [<a href="#rid15">15,16</a>]. However, phenytoin is not commonly used for chronic treatment in children because of concerns about adverse cosmetic effects that include hirsutism, gingival hyperplasia and coarse facial features. In addition, chronic phenytoin treatment has been associated with the potential for cerebellar atrophy and peripheral neuropathy. Carbamazepine appears to be effective but causes induction of the P450 system in the liver, which can be a concern in patients on multiple drugs that are metabolized by the liver.</p><p class="headingAnchor" id="H6"><span class="h3">Amitriptyline</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8605" href="/z/d/drug information/8605.html" rel="external">Amitriptyline</a>, at doses well below those used in the treatment of depression, has been shown to be effective in the treatment of chronic neuropathic pain [<a href="#rid17">17</a>]. At the lower doses used for neuropathic pain, serious side effects are uncommon. Nonetheless, an electrocardiogram should be obtained before and after beginning treatment since amitriptyline can cause adverse changes in cardiac conduction.</p><p>The recommended starting dose of <a class="drug drug_general" data-topicid="8605" href="/z/d/drug information/8605.html" rel="external">amitriptyline</a> in children is 0.1 mg/kg at night. This can be slowly increased over two to four weeks up to 0.5 to 2 mg/kg nightly.</p><p class="headingAnchor" id="H7"><span class="h1">CEREBROVASCULAR COMPLICATIONS</span><span class="headingEndMark"> — </span>Cerebral involvement in Fabry disease is due mainly to vasculopathy and a dilative arteriopathy in affected males and female carriers and may result in transient ischemic attack and almost always ischemic stroke. There is evidence of a resting cerebrovascular hyperperfusion in males with Fabry disease, which may cause increased shear stress and vessel wall damage over time [<a href="#rid18">18</a>]. The manifestations of stroke in Fabry disease are no different from ischemic stroke due to other common etiologies, and any stroke-related clinical deficit might occur. White matter abnormalities, seen best on fluid-attenuated inversion recovery (FLAIR) MRI images, are asymptomatic or related to subtle neuropsychological deficits [<a href="#rid19">19-24</a>]. Cerebrovascular complications are rare in children, but increase through adult life.</p><p>In data from 2446 patients in the observational Fabry Registry, the following results were reported [<a href="#rid25">25</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Stroke affected 138 patients (6 percent), including 86 of 1243 males (7 percent) and 52 of 1203 females (4 percent). Most strokes were ischemic (87 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Median age at first stroke for males and females was 39 and 45.7 years, respectively.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The proportion of patients with a first stroke prior to the diagnosis of Fabry disease in males and females was 50 and 38 percent, respectively. The proportion who experienced a stroke prior to renal or cardiac events for males and females was 71 and 77 percent.</p><p></p><p>From these data, the risk of stroke in male subjects 35 to 45 years of age with the classic form of Fabry disease is approximately 12-fold higher compared with the general population of similar age. In addition, stroke often occurs before the renal or cardiac manifestations of Fabry disease.</p><p>In an earlier literature review, the average age of onset for cerebrovascular symptoms of Fabry disease was 34 years for hemizygotes (n = 43) and 40 years for heterozygotes (n = 10) [<a href="#rid21">21</a>]. The most frequent cerebrovascular manifestations in hemizygotes were hemiparesis, vertigo, dizziness, diplopia, dysarthria, nystagmus, nausea, vomiting, head pain, hemiataxia, and ataxia of gait. Heterozygotes were prone to memory loss, dizziness, ataxia, hemiparesis, loss of consciousness, and hemisensory symptoms. The most common angiographic and pathologic features were elongation, ectasia, and tortuosity involving the vertebral and basilar arteries.</p><p>The cerebrovascular disease burden, in particular the white matter lesion load, increases with age. In a longitudinal study of 149 patients with Fabry disease, with a mean follow-up of seven years, factors associated with MRI progression of white matter lesions and cerebral infarctions were age and male sex [<a href="#rid26">26</a>]. In another MRI study, lesions were present in no male patient under age 26 compared with all patients over age 54 [<a href="#rid27">27</a>]. Of the patients with white matter lesions, neurologic symptoms were present in 37.5 percent.</p><p>White matter lesions also appear over time in female carriers. The Fabry Outcome Survey found that cerebrovascular events occurred in a high proportion of female and male patients (27 versus 12 percent) [<a href="#rid28">28,29</a>]. The mean age of cerebrovascular event onset was below 30 years in men and below 45 years in women. In a subsequent case series of patients with symptomatic Fabry disease, the frequency of marked white matter lesions was similar among male and female patients (4 of 13 versus 5 of 14 [31 versus 36 percent]) [<a href="#rid30">30</a>].</p><p>The high burden of white matter lesions and cerebrovascular events in women with Fabry disease (an X-linked disorder) may be explained by the lack of cross-correction from enzyme-replete to enzyme-deficient cells in females [<a href="#rid31">31</a>]. The risk of stroke is, in part, related to the ratio of mutated to normal cells in the vascular system resulting from random X-inactivation occurring in early development [<a href="#rid32">32</a>].</p><p class="headingAnchor" id="H8"><span class="h1">STROKE PREVENTION</span><span class="headingEndMark"> — </span>Standard ischemic stroke prevention measures are considered effective in secondary (and possibly primary) prevention for patients with Fabry disease, although this conclusion is based solely upon clinical experience [<a href="#rid33">33</a>].</p><p>These measures include the use of antiplatelet agents and, in particular, <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">clopidogrel</a>. In our clinical experience, stroke recurrence is frequent in patients with Fabry disease who are treated with <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a>. Therefore, for primary (in adult males with the classic form of the disease and a family history of stroke) and secondary stroke prevention, we suggest clopidogrel 75 mg once daily rather than aspirin. The combination drug <a class="drug drug_general" data-topicid="8664" href="/z/d/drug information/8664.html" rel="external">aspirin-extended-release dipyridamole</a> may be useful. Antihypertensive agents and statins are often used. These treatments are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/1086.html" rel="external">"Long-term antithrombotic therapy for the secondary prevention of ischemic stroke"</a> and  <a class="medical medical_review" href="/z/d/html/1120.html" rel="external">"Overview of secondary prevention of ischemic stroke"</a>.)</p><p class="headingAnchor" id="H9"><span class="h1">FABRY-SPECIFIC THERAPY</span><span class="headingEndMark"> — </span>Available Fabry-specific treatments include enzyme replacement therapy (<a class="drug drug_general" data-topicid="8515" href="/z/d/drug information/8515.html" rel="external">agalsidase alfa</a> and <a class="drug drug_general" data-topicid="8801" href="/z/d/drug information/8801.html" rel="external">agalsidase beta</a>) and pharmacologic chaperone therapy (<a class="drug drug_general" data-topicid="118740" href="/z/d/drug information/118740.html" rel="external">migalastat</a>). The effect of these interventions for the various manifestations of Fabry disease, including neuropathic pain symptoms and risk of ischemic stroke, is reviewed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/7207.html" rel="external">"Fabry disease: Treatment and prognosis"</a>.)</p><p class="headingAnchor" id="H2557816493"><span class="h1">REGISTRY</span><span class="headingEndMark"> — </span>A Fabry disease registry has been established to better understand the disease. Information is available online at https://www.registrynxt.com/. Participation in the registry is voluntary.</p><p class="headingAnchor" id="H655503161"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/122565.html" rel="external">"Society guideline links: Fabry disease"</a>.)</p><p class="headingAnchor" id="H90489997"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Peripheral neuropathy associated with Fabry disease causes an almost constant discomfort with paroxysmal burning pains of the hands and feet. (See <a class="local">'Small-fiber peripheral neuropathy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Prophylactic therapy for neuropathic pain with <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">gabapentin</a>, <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">carbamazepine</a>, <a class="drug drug_general" data-topicid="9769" href="/z/d/drug information/9769.html" rel="external">phenytoin</a>, or <a class="drug drug_general" data-topicid="8605" href="/z/d/drug information/8605.html" rel="external">amitriptyline</a> may provide relief. (See <a class="local">'Pain relief'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cerebral involvement in Fabry disease is due mainly to vasculopathy and a dilative arteriopathy in affected males and female carriers and may result in transient ischemic attack, stroke, aneurysms, acute blindness, and accumulation of symptomatic and asymptomatic white matter lesions. Cerebrovascular complications are rare in children, but increase through adult life. (See <a class="local">'Cerebrovascular complications'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For primary (in adult males with the classic form of the disease and a family history of stroke) and secondary prevention of ischemic stroke in adults or children with Fabry disease, we suggest antiplatelet therapy with <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">clopidogrel</a> (75 mg daily) rather than <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Antihypertensive agents and statins may be used as appropriate. (See <a class="local">'Stroke prevention'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Fabry-specific treatments, including enzyme replacement therapy (<a class="drug drug_general" data-topicid="8515" href="/z/d/drug information/8515.html" rel="external">agalsidase alfa</a> and <a class="drug drug_general" data-topicid="8801" href="/z/d/drug information/8801.html" rel="external">agalsidase beta</a>) and pharmacologic chaperone therapy (<a class="drug drug_general" data-topicid="118740" href="/z/d/drug information/118740.html" rel="external">migalastat</a>), are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/7207.html" rel="external">"Fabry disease: Treatment and prognosis"</a>.)</p><p></p><p class="headingAnchor" id="H446789031"><span class="h1">ACKNOWLEDGMENTS</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Robert Cruse, DO, and Raphael Schiffman, MD, MHSc, FAAN, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Schiffmann R. Fabry disease. Handb Clin Neurol 2015; 132:231.</a></li><li><a class="nounderline abstract_t">von Scheidt W, Eng CM, Fitzmaurice TF, et al. An atypical variant of Fabry's disease with manifestations confined to the myocardium. N Engl J Med 1991; 324:395.</a></li><li class="breakAll">Desnick RJ, Ioannou YA, Eng CM. α-galactosidase A deficiency: Fabry disease. In: The Online Metabolic and Molecular Bases of Inherited Disease, Valle DL, Antonarakis S, Ballabio A, et al. (Eds), McGraw-Hill. Available at: https://ommbid.mhmedical.com/content.aspx?bookid=2709&amp;sectionid=225546984 (Accessed on December 23, 2020).</li><li><a class="nounderline abstract_t">Toyooka K. Fabry disease. Curr Opin Neurol 2011; 24:463.</a></li><li><a class="nounderline abstract_t">Biegstraaten M, Hollak CE, Bakkers M, et al. Small fiber neuropathy in Fabry disease. Mol Genet Metab 2012; 106:135.</a></li><li><a class="nounderline abstract_t">Desnick RJ, Brady RO. Fabry disease in childhood. J Pediatr 2004; 144:S20.</a></li><li><a class="nounderline abstract_t">Luciano CA, Russell JW, Banerjee TK, et al. Physiological characterization of neuropathy in Fabry's disease. Muscle Nerve 2002; 26:622.</a></li><li><a class="nounderline abstract_t">Scott LJ, Griffin JW, Luciano C, et al. Quantitative analysis of epidermal innervation in Fabry disease. Neurology 1999; 52:1249.</a></li><li><a class="nounderline abstract_t">Vital A, Vital C, Maleville J. Fabry's disease: an ultrastructural study of muscle and peripheral nerve. Clin Neuropathol 1984; 3:168.</a></li><li><a class="nounderline abstract_t">Onishi A, Dyck PJ. Loss of small peripheral sensory neurons in Fabry disease. Histologic and morphometric evaluation of cutaneous nerves, spinal ganglia, and posterior columns. Arch Neurol 1974; 31:120.</a></li><li><a class="nounderline abstract_t">Godel T, Bäumer P, Pham M, et al. Human dorsal root ganglion in vivo morphometry and perfusion in Fabry painful neuropathy. Neurology 2017; 89:1274.</a></li><li><a class="nounderline abstract_t">MacDermot J, MacDermot KD. Neuropathic pain in Anderson-Fabry disease: pathology and therapeutic options. Eur J Pharmacol 2001; 429:121.</a></li><li><a class="nounderline abstract_t">Schuller Y, Linthorst GE, Hollak CE, et al. Pain management strategies for neuropathic pain in Fabry disease--a systematic review. BMC Neurol 2016; 16:25.</a></li><li><a class="nounderline abstract_t">Watson JC, Dyck PJ. Peripheral Neuropathy: A Practical Approach to Diagnosis and Symptom Management. Mayo Clin Proc 2015; 90:940.</a></li><li><a class="nounderline abstract_t">Lockman LA, Hunninghake DB, Krivit W, Desnick RJ. Relief of pain of Fabry's disease by diphenylhydantoin. Neurology 1973; 23:871.</a></li><li><a class="nounderline abstract_t">Lenoir G, Rivron M, Gubler MC, et al. [Fabry's disease. Carbamazepine therapy in acrodyniform syndrome]. Arch Fr Pediatr 1977; 34:704.</a></li><li><a class="nounderline abstract_t">Saarto T, Wiffen PJ. Antidepressants for neuropathic pain. Cochrane Database Syst Rev 2005; :CD005454.</a></li><li><a class="nounderline abstract_t">Moore DF, Scott LT, Gladwin MT, et al. Regional cerebral hyperperfusion and nitric oxide pathway dysregulation in Fabry disease: reversal by enzyme replacement therapy. Circulation 2001; 104:1506.</a></li><li><a class="nounderline abstract_t">Sher NA, Letson RD, Desnick RJ. The ocular manifestations in Fabry's disease. Arch Ophthalmol 1979; 97:671.</a></li><li><a class="nounderline abstract_t">Maisey DN, Cosh JA. Basilar artery aneurysm and Anderson-Fabry disease. J Neurol Neurosurg Psychiatry 1980; 43:85.</a></li><li><a class="nounderline abstract_t">Mitsias P, Levine SR. Cerebrovascular complications of Fabry's disease. Ann Neurol 1996; 40:8.</a></li><li><a class="nounderline abstract_t">Garzuly F, Maródi L, Erdös M, et al. Megadolichobasilar anomaly with thrombosis in a family with Fabry's disease and a novel mutation in the alpha-galactosidase A gene. Brain 2005; 128:2078.</a></li><li><a class="nounderline abstract_t">Buechner S, Moretti M, Burlina AP, et al. Central nervous system involvement in Anderson-Fabry disease: a clinical and MRI retrospective study. J Neurol Neurosurg Psychiatry 2008; 79:1249.</a></li><li><a class="nounderline abstract_t">Kolodny E, Fellgiebel A, Hilz MJ, et al. Cerebrovascular involvement in Fabry disease: current status of knowledge. Stroke 2015; 46:302.</a></li><li><a class="nounderline abstract_t">Sims K, Politei J, Banikazemi M, Lee P. Stroke in Fabry disease frequently occurs before diagnosis and in the absence of other clinical events: natural history data from the Fabry Registry. Stroke 2009; 40:788.</a></li><li><a class="nounderline abstract_t">Körver S, Longo MGF, Lima MR, et al. Determinants of cerebral radiological progression in Fabry disease. J Neurol Neurosurg Psychiatry 2020; 91:756.</a></li><li><a class="nounderline abstract_t">Crutchfield KE, Patronas NJ, Dambrosia JM, et al. Quantitative analysis of cerebral vasculopathy in patients with Fabry disease. Neurology 1998; 50:1746.</a></li><li><a class="nounderline abstract_t">MacDermot KD, Holmes A, Miners AH. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. J Med Genet 2001; 38:769.</a></li><li><a class="nounderline abstract_t">Mehta A, Ricci R, Widmer U, et al. Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. Eur J Clin Invest 2004; 34:236.</a></li><li><a class="nounderline abstract_t">Fellgiebel A, Müller MJ, Mazanek M, et al. White matter lesion severity in male and female patients with Fabry disease. Neurology 2005; 65:600.</a></li><li><a class="nounderline abstract_t">Fuller M, Mellett N, Hein LK, et al. Absence of α-galactosidase cross-correction in Fabry heterozygote cultured skin fibroblasts. Mol Genet Metab 2015; 114:268.</a></li><li><a class="nounderline abstract_t">Echevarria L, Benistan K, Toussaint A, et al. X-chromosome inactivation in female patients with Fabry disease. Clin Genet 2016; 89:44.</a></li><li><a class="nounderline abstract_t">Moore DF, Kaneski CR, Askari H, Schiffmann R. The cerebral vasculopathy of Fabry disease. J Neurol Sci 2007; 257:258.</a></li></ol></div><div id="topicVersionRevision">Topic 6194 Version 21.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26564084" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Fabry disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1846223" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : An atypical variant of Fabry's disease with manifestations confined to the myocardium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1846223" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : An atypical variant of Fabry's disease with manifestations confined to the myocardium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21825987" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Fabry disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22497776" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Small fiber neuropathy in Fabry disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15126980" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Fabry disease in childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12402283" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Physiological characterization of neuropathy in Fabry's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10214752" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Quantitative analysis of epidermal innervation in Fabry disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6434215" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Fabry's disease: an ultrastructural study of muscle and peripheral nerve.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4135101" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Loss of small peripheral sensory neurons in Fabry disease. Histologic and morphometric evaluation of cutaneous nerves, spinal ganglia, and posterior columns.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28835396" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Human dorsal root ganglion in vivo morphometry and perfusion in Fabry painful neuropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11698033" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Neuropathic pain in Anderson-Fabry disease: pathology and therapeutic options.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26911544" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Pain management strategies for neuropathic pain in Fabry disease--a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26141332" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Peripheral Neuropathy: A Practical Approach to Diagnosis and Symptom Management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4578349" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Relief of pain of Fabry's disease by diphenylhydantoin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/412484" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : [Fabry's disease. Carbamazepine therapy in acrodyniform syndrome].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16034979" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Antidepressants for neuropathic pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11571244" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Regional cerebral hyperperfusion and nitric oxide pathway dysregulation in Fabry disease: reversal by enzyme replacement therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/106811" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : The ocular manifestations in Fabry's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6766499" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Basilar artery aneurysm and Anderson-Fabry disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8687196" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Cerebrovascular complications of Fabry's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15947062" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Megadolichobasilar anomaly with thrombosis in a family with Fabry's disease and a novel mutation in the alpha-galactosidase A gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18535022" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Central nervous system involvement in Anderson-Fabry disease: a clinical and MRI retrospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25492902" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Cerebrovascular involvement in Fabry disease: current status of knowledge.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19150871" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Stroke in Fabry disease frequently occurs before diagnosis and in the absence of other clinical events: natural history data from the Fabry Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32317398" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Determinants of cerebral radiological progression in Fabry disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9633721" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Quantitative analysis of cerebral vasculopathy in patients with Fabry disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11732485" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15025684" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16116124" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : White matter lesion severity in male and female patients with Fabry disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25468650" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Absence ofα-galactosidase cross-correction in Fabry heterozygote cultured skin fibroblasts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25974833" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : X-chromosome inactivation in female patients with Fabry disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17362993" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : The cerebral vasculopathy of Fabry disease.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
